Isochroman compound
Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
wherein T is N or CH;
R 1 and R 2 are each independently H, F, Cl, Br, I, or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted by 1, 2, or 3 R a ;
each R a is independently F, Cl, Br, I, —CN, —OH or —NH 2 ;
R 3 and R 4 are each independently H, F, Cl, Br, I, CN, C 1-3 alkyl, C 1-3 alkoxy,
wherein the C 1-3 alkyl is optionally substituted by 1, 2 or 3 R e ;
R b and R c are each independently H, —CH 3 , —CH 2 CH 3 , —(CH 2 ) 2 CH 3 or —CH(CH 3 ) 2 ;
R d is —CH 3 , —CH 2 CH 3 , —(CH 2 ) 2 CH 3 or —CH(CH 3 ) 2 ;
each R e is independently F, Cl, Br, I, —CN, —OH or —NH 2 .
2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound has a structure represented by formula (I-1):
3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound has a structure represented by formula (I-3) or (I-4):
wherein the carbon atom with “*” is a chiral carbon atom, which exists in the form of (R) or (S) single enantiomer or enriched in one enantiomer.
4. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 and R 2 are each independently H, F, Cl, Br, I or —CH 3 , wherein the —CH 3 is optionally substituted by 1, 2 or 3 R a .
5. The compound or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 is H, F, Cl, Br, I or —CH 3 ; R 2 is H.
6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 and R 4 are each independently H, F, Cl, Br, I, CN, —CH 3 , —OCH 3 ,
wherein the —CH 3 is optionally substituted by 1, 2 or 3 R e .
7. The compound or the pharmaceutically acceptable salt thereof according to claim 6 , wherein R 3 and R 4 are each independently H, F, —CH 3 , —CHF 2 , —OCH 3 ,
8. The compound or the pharmaceutically acceptable salt thereof according to claim 7 , wherein R 3 and R 4 are each independently H.
9. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
10. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
11. A method for treating liver cancer in a subject in need thereof, comprising: administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
12. A method for treating liver cancer in a subject in need thereof, comprising: administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 9 to the subject.
13. A method for treating liver cancer in a subject in need thereof, comprising: administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 10 to the subject.
14. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound has a structure represented by formula (I-2):